Fifty strains of Mycoplasma pneumoniae in L cells were tested for susceptibility to macrolide antibiotics. Rokitamycin, a new macrolide antibiotic, was most active against these organisms, with an MIC for 90% of strains of 0.007 ,ug/ml. The MICs of erythromycin, josamycin, and kitasamycin for 90% of strains were 0.03, 0.03, and _0.06 ,ug/ml, respectively. Based on these results, rokitamycin is a promising antibiotic for the treatment of mycoplasmal infections, and further clinical investigations are needed.
rolide and tetracycline antibiotics have been widely used, because of the susceptibilities of M. pneumoniae to these antibiotics as assayed by the agar method (1, 10) . Because the adherence of mycoplasmas to the epithelium of the respiratory tract is an initial step in successful colonization (2, 4, 6, 9) , it mnight be relevant for the treatment of M. pneumoniae infections to examine the effects of antibiotics on.the elimination of attached and colonized mycoplasmas from the surface of cells (1, 7, 13) .
The purpose of this study was to determine the in vitro activities of macrolide antibiotics, including rokitamycin (RKM; TM-19Q), one of the acyl derivatives of 16-membered macrolides (11, 12) , against recent clinical isolates of M. pneumoniae, comparing MICs determined by the agar dilution method and the minimum concentrations to eliminate M. pneumoniae from infected L cells.
Forty-nine strains of M. pneumoniae isolated from throat swabs of patients with pneumonia plus the standard M. pneumoniae strain, FH, were used. Isolates were subcultured fewer than five times in broth and stocked at -80°C until use. The antibiotics used were erythromycin (EM; Shionogi Pharmaceutical Co. Ltd., Osaka, Japan), josamycin (JM; Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan), and kitasamycin (leucomycin; LM) and RKM (Toyojozo Co. Ltd., Tokyo, Japan). confirmed whether the cell cultures were "cured" by using DNA staining. As shown in Fig. 2 , the microorganisms had completely disappeared 3 days after treatment with RKM (1 _,g/ml), and the cells looked healthy. The cured L cells were continuously cultured for more than 1 month without the antibiotics, and no mycoplasmas were found.
The MICs determined by the agar dilution method for individual strains were compared with the minimum doses needed to eliminate the microorganisms from L cells (Fig. 3) . The results showed that the doses of RKM for the elimination of M. pneumoniae from L cells were lower than the MICs in 41 strains and higher in 6 strains. Those of JM and LM were almost proportional to their MICs. However, it is interesting that relatively high doses of EM were required for the elimination of mycoplasmas (more than 80% of strains).
We demonstrated the susceptibilities of M. pneumoniae in L cells to macrolide antibiotics. The assay system used to determine the activities of antibiotics in this study might be clinically useful for the treatment of infections caused by M. pneumoniae, because attachment of viable mycoplasmas to the respiratory epithelium is necessary for the initiation of infection (2, 7, 9) . The mechanisms of attachment of M. pneumoniae to L cells are not clear, but the attachment might be due to a sialic acid-containing region, in a manner similar to that of the attachment of M. pneumoniae to the respiratory epithelium and erythrocytes (2, 6) .
It is well known that macrolide antibiotics, especially EM, are very active against M. pneumoniae in vitro (1, 10 
